



Sciences de la Vie et de la Santé  
Master BMC, Universités Paris Descartes – Paris Diderot

Parcours : **Biologie et Développement Cellulaires**

<http://www.master2bdc.fr/>

Fiche de Projet de Stage M2, Année 2020-2021

<b>Institut Cochin, INSERM U1016</b> <b>Receptor Signalling &amp; Molecular Scaffolds</b>	<b>Responsable du Stage :</b>
<b>ED d'appartenance : BioSPC</b>	<b>Mark SCOTT</b> Institut Cochin, 27 rue du Fg St Jacques, 75014 Paris
<b>Responsable de l'Equipe : S. Marullo</b>	Email : mark.scott@inserm.fr Tel : 01 40 51 65 48

**Titre du projet : A new molecular partner for Tumour Suppressor PTEN: implications for cell polarity and migration**

**Résumé du Projet de Stage** (en 300 mots maximum, mots clés en gras)

Our group studies the regulation of important cellular communication pathways and how these may go awry in cancer settings. We have a particular interest in the **Tumour Suppressor PTEN**. PTEN is a non-redundant **phosphatase** that dephosphorylates the lipid phosphatidyl (3,4,5) trisphosphate (PIP3) and thus inhibits the pro-proliferative **PI3K/AKT signalling** pathway. By opposing the PI3K/AKT pathway, PTEN regulates many key **cell fate** decisions such as **proliferation, survival** and **motility**. These processes often go awry in **cancer** leading to inappropriate cell growth, migration and invasion.

Regulation of PTEN levels, localization and activity are subject to tight control: PTEN expression is controlled transcriptionally, post-transcriptionally via oncogenic miRNAs, and also at the **post-translational level** by phosphorylation, oxidation, acetylation, ubiquitination as well as **protein-protein interactions**. While the *PTEN* gene is mutated in a wide variety of human cancers, downregulation of PTEN activity can also occur via changes in posttranslational regulation, in the absence of any *PTEN* gene alteration.

Following yeast 2-hybrid screening of a **breast cancer** cDNA library using PTEN as bait, we have identified a key **polarity protein** as a new molecular partner for PTEN. The project will involve investigating the effect of targeted gene disruption of *PTEN* and partner on signal transduction, cell polarity and migration, using breast cancer cell lines. The regions involved in PTEN-partner interaction will also be mapped using biochemical approaches. Techniques that will be used include yeast 2-hybrid, co-immunoprecipitations, BRET, gene targeting and cell migration assays.

#### **Publications de l'équipe, relatives au stage proposé**

-Kotelevets L, Trifault B, Chastre E and **Scott MGH**. Post-translational regulation and conformational plasticity of PTEN. **Cold Spring Harbor Perspect Med**. doi: 10.1101/cshperspect.a036095 (2020).

-Alexander R, Lot I, Saha K, Abadie G, Lambert M, Decosta E, Kobayashi H, Beautrait A, Borrull A, Asnacios A, Bouvier M, **Scott MGH**, Marullo S, and Enslin H. Beta-arrestins operate an on/off control switch for focal adhesion kinase activity. **Cell Mol Life Sci**. doi: 10.1007/s00018-020-03471-5 (2020).

-Javadi A, Deevi RK, Evergren E, Blondel-Tepaz E, Baillie GS, **Scott MGH** and Campbell FC. PTEN controls glandular morphogenesis through a juxtamembrane  $\beta$ -arrestin1/ARHGAP21 scaffolding complex. **eLife** 6. pii: e24578 (2017).

-Misticone S, Lima-Fernandes E and **Scott MGH**. Rapid detection of dynamic PTEN regulation in living cells using intramolecular BRET. **Methods Mol Biol**. 1388: 95-110 (2016).

-Paradis, JS, Ly S, Blondel-Tepaz E, Galan, JA, Beautrait A, **Scott MGH**, Enslin H, Marullo, S, Roux PP and Bouvier M. Receptor sequestration in response to ERK1/2-mediated phosphorylation of  $\beta$ arrestin-2 determines steady-state levels of GPCR cell surface expression. **Proc Natl Acad Sci U S A**. 112 E51160-8 (2015).

-Lima-Fernandes E, Misticone S, Boullaran C, Paradis JS, Enslin H, Roux PP, Bouvier M, Baillie GS, Marullo S and **Scott MGH**. A biosensor to monitor dynamic regulation and function of tumour suppressor PTEN in living cells. **Nat Commun**. 5:4431 (2014).

-Lima-Fernandes E, Enslin H, Camand E, Kotelevets L, Boullaran C, Achour L, Benmerah A, Pitcher JA, Chastre E, Etienne-Manneville S, Marullo S and **Scott MGH**. Distinct functional outputs of Tumor Suppressor PTEN signaling are controlled by dynamic association with  $\beta$ -arrestins. **EMBO J** 6; 30, 2557-2568 (2011).